MA20150436A1 - Préparation pharmaceutique - Google Patents

Préparation pharmaceutique

Info

Publication number
MA20150436A1
MA20150436A1 MA37777A MA37777A MA20150436A1 MA 20150436 A1 MA20150436 A1 MA 20150436A1 MA 37777 A MA37777 A MA 37777A MA 37777 A MA37777 A MA 37777A MA 20150436 A1 MA20150436 A1 MA 20150436A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical preparation
antibody
high concentration
present
viscosity
Prior art date
Application number
MA37777A
Other languages
English (en)
Other versions
MA37777B1 (fr
Inventor
Andrew Jeffrey Yates
James Gregory Clipstone
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA20150436(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of MA20150436A1 publication Critical patent/MA20150436A1/fr
Publication of MA37777B1 publication Critical patent/MA37777B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des procédés et des moyens permettant de réduire la viscosité d'une préparation pharmaceutique comprenant un anticorps ou une autre protéine thérapeutique à une concentration élevée. La présente invention concerne une préparation pharmaceutique liquide qui comprend un anticorps à une concentration élevée et présente une viscosité réduite n'empêchant pas le traitement ou l'injection de ladite préparation pharmaceutique.
MA37777A 2012-06-21 2013-06-20 Préparation pharmaceutique MA37777B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662621P 2012-06-21 2012-06-21
PCT/EP2013/062898 WO2013190047A1 (fr) 2012-06-21 2013-06-20 Préparation pharmaceutique

Publications (2)

Publication Number Publication Date
MA20150436A1 true MA20150436A1 (fr) 2015-11-30
MA37777B1 MA37777B1 (fr) 2017-07-31

Family

ID=48745904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37777A MA37777B1 (fr) 2012-06-21 2013-06-20 Préparation pharmaceutique

Country Status (25)

Country Link
US (1) US20150150979A1 (fr)
EP (1) EP2864356A1 (fr)
JP (1) JP6157611B2 (fr)
KR (1) KR20150032941A (fr)
CN (1) CN104520326A (fr)
AR (1) AR091530A1 (fr)
AU (1) AU2013279347A1 (fr)
BR (1) BR112014031841A2 (fr)
CA (1) CA2876012A1 (fr)
CL (1) CL2014003283A1 (fr)
CO (1) CO7170174A2 (fr)
EA (1) EA201590061A1 (fr)
EC (1) ECSP15002095A (fr)
HK (1) HK1205146A1 (fr)
IL (1) IL235921A0 (fr)
MA (1) MA37777B1 (fr)
MX (1) MX2014014717A (fr)
NZ (1) NZ702342A (fr)
PE (1) PE20150190A1 (fr)
PH (1) PH12014502596A1 (fr)
SG (1) SG11201407779YA (fr)
TN (1) TN2014000498A1 (fr)
TW (1) TW201406398A (fr)
WO (1) WO2013190047A1 (fr)
ZA (1) ZA201409020B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3043775B1 (fr) 2013-09-11 2020-11-04 Eagle Biologics, Inc. Formulations de protéines liquides contenant des agents abaissant la viscosité
KR102497368B1 (ko) 2014-10-01 2023-02-10 이글 바이올로직스 인코포레이티드 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
JP6830153B2 (ja) * 2016-05-28 2021-02-17 ラジーヴ ガンディー センター フォー バイオテクノロジー， アン オウトノマス インスティテュート アンダー ザ デパートメント オブ バイオ−テクノロジー， ガバメント オブ インディアＲａｊｉｖ Ｇａｎｄｈｉ Ｃｅｎｔｒｅ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ａｎ Ａｕｔｏｎｏｍｏｕｓ Ｉｎｓｔｉｔｕｔｅ Ｕｎｄｅｒ Ｔｈｅ Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｂｉｏ−Ｔｅｃｈｎｏｌｏｇｙ， Ｇｏｖｅｒｎｍｅｎｔ Ｏｆ Ｉｎｄｉａ 肝細胞癌の治療薬としてのウットロシドｂ及びその誘導体
BR112019006853B1 (pt) * 2016-10-31 2021-08-24 Fresenius Kabi Deutschland Gmbh Composição farmacêutica líquida, seu método de fabricação, seu uso, kit e dispositivo de liberação de fármaco que a compreendem e método de fabricação do dito dispositivo
AU2018207367B2 (en) * 2017-01-11 2024-02-15 Celltrion Inc. Stable Liquid Formula
CA3063324A1 (fr) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. Formulations de proteines a haute concentration ayant une viscosite reduite
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20230405018A1 (en) * 2020-11-18 2023-12-21 Bexson Biomedical, Inc. Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US8658773B2 (en) * 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
JP4869064B2 (ja) * 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
US20090238820A1 (en) * 2005-03-08 2009-09-24 Allan Corey M ANTI-MAdCAM ANTIBODY COMPOSITIONS
US20090060906A1 (en) * 2007-01-09 2009-03-05 Wyeth Anti-IL-13 antibody formulations and uses thereof
MX2009013593A (es) * 2007-06-14 2010-01-20 Biogen Idec Inc Formulaciones de anticuerpos.
MX2012012743A (es) * 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
BR112012028920B1 (pt) * 2010-05-14 2021-03-23 Amgen Inc. Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína
CN103108658B (zh) * 2010-07-02 2015-08-19 米迪缪尼有限公司 抗体制剂
AU2012243126A1 (en) * 2011-04-07 2013-10-17 Glaxosmithkline Llc Formulations with reduced viscosity

Also Published As

Publication number Publication date
JP2015520206A (ja) 2015-07-16
BR112014031841A2 (pt) 2017-06-27
PE20150190A1 (es) 2015-02-13
AU2013279347A1 (en) 2014-12-18
TN2014000498A1 (en) 2016-03-30
MA37777B1 (fr) 2017-07-31
MX2014014717A (es) 2015-03-06
CN104520326A (zh) 2015-04-15
EP2864356A1 (fr) 2015-04-29
KR20150032941A (ko) 2015-03-31
SG11201407779YA (en) 2015-02-27
HK1205146A1 (en) 2015-12-11
WO2013190047A1 (fr) 2013-12-27
JP6157611B2 (ja) 2017-07-05
TW201406398A (zh) 2014-02-16
EA201590061A1 (ru) 2015-05-29
AR091530A1 (es) 2015-02-11
CL2014003283A1 (es) 2016-04-01
PH12014502596A1 (en) 2015-01-12
CO7170174A2 (es) 2015-01-28
NZ702342A (en) 2016-07-29
ECSP15002095A (es) 2015-11-30
CA2876012A1 (fr) 2013-12-27
IL235921A0 (en) 2015-01-29
US20150150979A1 (en) 2015-06-04
ZA201409020B (en) 2016-09-28

Similar Documents

Publication Publication Date Title
MA20150436A1 (fr) Préparation pharmaceutique
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
Boczek et al. The role of G protein-coupled receptors (GPCRs) and calcium signaling in schizophrenia. Focus on GPCRs activated by neurotransmitters and chemokines
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MX350010B (es) Inhibidores syk de imidazopiridinas.
MA40041A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
ATE516814T1 (de) 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
BR112015025711A8 (pt) uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
BR112013008140A2 (pt) "compostos imidazotriazinona".
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA38986A3 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
MA39342B2 (fr) Anticorps il -21
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA35165B1 (fr) Induction de tolérance immune par utilisation de méthotrexate
FR3044312B1 (fr) Polypeptides mutes de hev et leur utilisation pour le dosage d'anticorps anti-hev
FR3061021B1 (fr) Antagoniste specifique de tlr4 dans le traitement du myelome multiple
MA35927B1 (fr) Polythérapie pour le traitement d'un cancer de l'ovaire